{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:45:44Z","timestamp":1776440744980,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Science, Information Communication Technology (ICT) & Future Planning","award":["NRF-2013M3A9B5075839"],"award-info":[{"award-number":["NRF-2013M3A9B5075839"]}]},{"name":"Ministry of Education (ME) of Korea","award":["22A20130012250"],"award-info":[{"award-number":["22A20130012250"]}]},{"name":"ME","award":["2018R1A6A1A03025108"],"award-info":[{"award-number":["2018R1A6A1A03025108"]}]},{"name":"Ministry of Health and Welfare, Republic of Korea","award":["HI16C1761"],"award-info":[{"award-number":["HI16C1761"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.pharep.2018.12.005","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T14:43:12Z","timestamp":1544798592000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model"],"prefix":"10.1007","volume":"71","author":[{"given":"Okki","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-8145","authenticated-orcid":false,"given":"You-jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hwe","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2018.12.005_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejvs.2003.09.014","article-title":"The role of statins in vascular disease","volume":"27","author":"Laws","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.pharep.2018.12.005_bib0010","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharep.2018.12.005_bib0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2249.2012.04564.x","article-title":"Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells","volume":"168","author":"Iwata","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"II","key":"10.1016\/j.pharep.2018.12.005_bib0020","first-page":"I39","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2018.12.005_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuroscience.2015.11.053","article-title":"Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells","volume":"314","author":"Kata","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharep.2018.12.005_bib0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pds.3199","article-title":"Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in the Health Improvement Network","volume":"21","author":"Rowan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pharep.2018.12.005_bib0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/FJC.0b013e31804a5e34","article-title":"Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells","volume":"49","author":"Kim","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/tpj.2015.91","article-title":"The effects of rosuvastatin on lipid-lowering, inflammatory, antioxidant and fibrinolytics blood biomarkers are influenced by Val16Ala superoxide dismutase manganese-dependent gene polymorphism","volume":"16","author":"Duarte","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pharep.2018.12.005_bib0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejvs.2009.01.008","article-title":"Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation","volume":"37","author":"Cleanthis","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.pharep.2018.12.005_bib0050","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0055","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.intimp.2010.06.008","article-title":"Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-kappaB inactivation: not involved in cAMP mechanisms","volume":"10","author":"Park","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/iub.309","article-title":"Tumor necrosis factor, lymphotoxin and cancer","volume":"62","author":"Drutskaya","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.pharep.2018.12.005_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-alpha signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.pharep.2018.12.005_bib0070","article-title":"Pravastatin and sarpogrelate synergistically ameliorate atherosclerosis in LDLr-Knockout mice","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharep.2018.12.005_bib0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/fcp.12195","article-title":"Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats","volume":"30","author":"da Motta","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.smim.2014.02.009","article-title":"TNF and MAP kinase signalling pathways","volume":"26","author":"Sabio","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.pharep.2018.12.005_bib0090","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1160\/TH14-11-0947","article-title":"Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD","volume":"114","author":"Muller","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharep.2018.12.005_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/VHRM.S2048","article-title":"Relative safety profiles of high dose statin regimens","volume":"4","author":"Escobar","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pharep.2018.12.005_bib0100","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2005-03-1247","article-title":"Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure","volume":"106","author":"Pignatelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharep.2018.12.005_bib0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00015385.2017.1321908","article-title":"Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells","volume":"73","author":"Kim","year":"2018","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0115","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.3748\/wjg.v23.i25.4559","article-title":"Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model","volume":"23","author":"Shin","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharep.2018.12.005_bib0120","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12280","article-title":"Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis","volume":"35","author":"Park","year":"2017","journal-title":"Cardiovasc Ther"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018304456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018304456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:50Z","timestamp":1752611870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.12.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1734114018304456"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.12.005","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}